Off-Label Use of Monoclonal Antibodies in Developing Countries. (PubMed, Am J Ther) - Oct 21, 2026 - "Rituximab was widely used in clinical practice; however, its implementation protocols and safety-monitoring practices varied considerably. In light of these findings, it is important to distinguish between off-label use and inappropriate use, and to ensure that treatment decisions are evaluated against current evidence, clinical guidelines, and indication-specific criteria."
Journal
|
|
Fatemeh Alizadeh Bengar; Hossein Khalili; Parinaz Sadat Mahmoudi
|